Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 7/20 | 0.45 |
| ▸ | ACACA | Q13085 | 4/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377073 | 0.86 | KMT2A (0.56) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL190838 | 0.86 | KMT2A (0.56) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL3942686 | 0.86 | KMT2A (0.56) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL3816616 | 0.86 | KMT2A (0.56) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL18534331 | 0.83 | EPHX1 (0.52) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL14408855 | 0.83 | KMT2A (0.49) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL5126670 | 0.83 | KMT2A (0.53) | KMT2AEPHX1DRD2ACACBACACA | |
| Bicarbonate SCHEMBL1580718 | 0.82 | KMT2A (0.57) | KMT2AEPHX1DRD2ACACBACACA | |
| Formaldehyde SCHEMBL28082239 | 0.82 | KMT2A (0.54) | KMT2AEPHX1DRD2ACACBACACA | |
| SCHEMBL10209101 | 0.82 | EPHX1 (0.54) | KMT2AEPHX1DRD2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1183245-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2007-05-09 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| EP-1194421-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | EP | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| US-6218408-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6214853-B1 | DIETETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-10 | — | — | US | disclosed |
| US-6124331-A | TREATING ABNORMAL FEEDING DISORDERS (OBESITY AND BULIMIA NERVOSA), SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | KMT2A 3078/4885EPHX1 3953/4885DRD2 533/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | KMT2A 3078/4885EPHX1 3953/4885DRD2 533/4885 |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | KMT2A 3383/4885EPHX1 3465/4885DRD2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.